As tax season approaches, Clayton Homes, America’s largest homebuilder**, is offering potential homebuyers a great way to get the most out of their tax refund in 2015 with its Avoid Refund Regret campaign.
The program, which runs through March 31, offers those purchasing a new Clayton Home an extra incentive towards homeownership during the beginning of 2015.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7413931-clayton-homes-avoid-refund-regret/
Rosecrance, one of the country’s leading teen substance abuse treatment centers, has launched a traveling art exhibit to help parents understand teenagers’ points of view about pressures they encounter and how they are faced with the potential to use, and abuse, substances. Developed by teen patients participating in an art therapy program at Rosecrance’s adolescent campus in Rockford, IL, “In My Shoes” encourages parents to understand their teen’s point of view and actively parent to help teens navigate today’s confusing environment.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7348551-rosecrance-s-in-my-shoes-traveling-art-exhibit-parents-teenagers-prevent-substance-abuse/
More than 15 percent of reproductive-aged women have filled a prescription for an antidepressant medication during the years 2008–2013, according to a new analysis published today in the Centers for Disease Control and Prevention (CDC)’s Morbidity and Mortality Weekly Report (MMWR).
January is National Birth Defects Prevention Month and the CDC is working with the March of Dimes to raise awareness about the use of antidepressant medications by women of reproductive age, and what women should know and do for their own health and that of their babies. There is conflicting evidence about the potential link between some antidepressants and certain birth defects. Some commonly used antidepressants are sertraline (Zoloft), bupropion (Wellbutrin, Zyban), and citalopram (Celexa).
To view the multimedia release go to:
http://www.multivu.com/players/English/7709851-march-of-dimes-antidepressant-pregnancy-study/
The Amgen Foundation announced today that it will invest more than $4 million to support and strengthen the Amgen Biotech Experience program across the United States, Puerto Rico, United Kingdom and Ireland. The Amgen Biotech Experience includes an engaging series of labs that effectively bring biotechnology into classrooms. This new commitment will also strengthen the program’s alignment with the United States’ Next Generation Science Standards, which are focused on engaging students in more authentic science learning experiences. With the support of Education Development Center, Inc. (EDC), the global nonprofit leading the Amgen Biotech Experience Program Office, the investment is expected to empower 1,000 teachers who will reach more than 150,000 new students with the labs over the next two years.
“We are very excited to extend our commitment to the Amgen Biotech Experience, a program that began 25 years ago, with the intent to ignite a deep passion for innovation and scientific discovery in students,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “This program, which provides advanced biotech curriculum and professional-grade lab equipment at no cost to schools, has opened countless students’ eyes to the world of biotechnology, fueling potential long term advancements to both medicine and society.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7414055-amgen-biotech-experience-grant/
Dame Stephanie Shirley, the British Government�s Founding Ambassador for Philanthropy, today launched AmbassadorsForPhilanthropy.com, a global movement which brings together charities, companies, philanthropists and governments for a worldwide effort �to unleash global giving\'s potential�.
Dame Stephanie is a leading philanthropist who has donated millions from her self-made software business. She and her team are devoted to transforming the potential of philanthropy into a dynamic reality by �giving philanthropists a voice�.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/ambassadorsforphilanthropy/52163/
Volvo Cars’ all-new XC90 – which will be revealed in August – will offer the most comprehensive and technologically sophisticated standard safety package available in the automotive industry. The new technologies will take the company a significant step closer to its vision that no one will be killed or seriously injured in a new Volvo car by 2020.
The XC90 is the first car in the world with technology that features automatic braking if the driver turns in front of an oncoming car. This is a common scenario at busy city crossings as well as on highways, where the speed limits are higher. The all-new Volvo XC90 detects a potential crash and brakes automatically in order to avoid a collision or mitigate the consequences of a crash.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400582-all-new-volvo-XC90-safest-car
Too many children in India are unable to realize their potential due to poverty and malnutrition. Under-nutrition is a grave problem that hits children the hardest affecting survival and even their participation in education. With an aim that no child should miss out school due to hunger, this organization provides food for education(mid day meal) to 1.3 million school children every day in India.
Donate online just Rs.750 and feed a child for one whole year to continue their education.
Know more about Akshaya Patra: http://www.akshayapatra.org
Support us by feeding a child : https://www.akshayapatra.org/onlinedonations
Follow us via social media:
https://www.facebook.com/TheAkshayapatraFoundation
https://twitter.com/AkshayaPatra
http://www.linkedin.com/company/the-akshaya-patra-foundation
http://www.pinterest.com/akshayapatra
http://www.youtube.com/user/akshayapatra
Construction is the most dangerous industry in Canada, accounting for 22% of all fatalities, followed by manufacturing, government services, and transportation. Furthermore, among the most hazardous construction-related activities is the use of aerial platforms.
The BIS - Aerial Lift Online Course teaches you the fundamental principles of safe operating procedures and helps to eliminate potential risks to straight telescoping, articulating, and scissor lift aerial platforms.
To learn more about this course, visit: https://www.trainanddevelop.ca/courses/aerial-platforms/
ADP, a leading global technology company providing human capital management (HCM) solutions, brings a profound understanding of the changing world of work to today’s launch of its first-ever 360-degree brand campaign, “What Are You #WorkingFor?”. The key insight underscoring the integrated campaign is that work is about more than what you do — it’s about achieving something greater for one’s self and others.
For 70 years, ADP has reimagined the workplace by designing cutting-edge products, premium services and exceptional experiences that touch millions of people’s lives daily. ADP was the first to deliver automation in the HCM space, first in the cloud, first to provide a mobile HCM app and first to create an HCM marketplace. This legacy of innovation and insight into the design of the employee experience inspired ADP’s new brand platform, “Always Designing for People,” also unveiled today. Representing ADP’s new tagline, the brand platform is an expression of what ADP stands for and reinforces its relentless determination to rethink a better, more personalized world at work so everyone can achieve their full potential.
To view the multimedia release go to:
https://www.multivu.com/players/English/8504551-adp-rebrand-always-designing-for-people-what-are-you-workingfor/
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Triax Technologies Inc and Washington Youth Soccer have announced a long-term partnership to track and assess head impacts among top level youth players. Findings from the large scale collection of data will be used to identify trends and potential risks to inform training protocols which will be publically shared to encourage best practices.
Players from the Washington Youth Soccer Elite Player Development (EPD) program (U12-U18) will wear the Triax Technologies Smart Impact Monitors (SIM™) as they compete in the prestigious US Youth Soccer Region IV Olympic Development Program (ODP) Championships January 8–11 in Phoenix, AZ, and will continue throughout their careers with Washington Youth Soccer.
Triax SIM™ devices are worn in comfortable, unobtrusive headbands to record head impacts, and transmit data in real time from the field to a smart phone or tablet on the sideline. This cutting edge technology allows players to track up to 180 individual head impacts measuring the G–force of direct hits and jarring through linear and rotational measures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7416151-triax-technologies-impact-monitoring/
AbbVie (NYSE:ABBV) today marks its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they ring the first opening bell of 2013 at the New York Stock Exchange.
With a rich, 125-year heritage of developing pharmaceuticals, AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. A global enterprise that serves patients in more than 170 countries, AbbVie launches with an estimated $18 billion in annual revenues and a strong commitment to creating shareholder value through long-term growth potential and the continuation of the company’s history of shareholder dividends.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59757-abbvie-celebrates-launch-as-new-biopharmaceutical-company
